EE570 Economic Evaluation of Tislelizumab for the Treatment of Second-Line Oesophageal Squamous Cell Carcinoma: A Lifetime Partition Survival Model
Abstract
Authors
E Priedane M Griffiths J. Smith-Tilley C Davies I Ferrusi A Prieto Patron K Wang S Mardiguian